Presenter: S. Massarweh Presenter's Affiliation: Baylor Breast Center Type of Session: Scientific
Resistance of some breast cancers to endocrine therapy remains a problem for clinicians.
Research into preventing or reversing endocrine resistance in breast cancer is needed.
Some prior studies have shown Her2-positive tumors to be less responsive to Tamoxifen therapy.
The presenter first showed some data, utilizing a nude mouse xenograft model for ER+/HER2+ tumors (MCF-7/HER2-18 cells).
Mice were randomized to estrogen deprivation, estradiol (E2) administration, or tamoxifen. Tumors in the E2-deprived mice were stable in size. Tumors in the E2-supplemented mice grew rapidly. Mice which received tamoxifen had tumors which were initially stable in size, but later became endocrine unresponsive, growing in size.
Data seem to suggest "cross-talk" between epidermal growth factor receptor (EGFR) and the HER2 receptor pathway, leading to endocrine resistance in the tumor.
The researchers then evaluated the role of ZD1839 ("Iressa"), an orally active, selective EGFR tyrosine kinase inhibitor that blocks EGFR and HER2 activation. The goal was to evaluate whether Iressa modulated endocrine resistance in these mice.
Materials and Methods
The researchers repeated their prior nude mouse tumor model experiment, this time utilizing a six-arm design. Mice were randomized initially to estradiol supplementation, estrogen repression, or Tamoxifen.
Mice in these 3 arms were then randomized to Iressa or control.
Iressa modestly diminished tumor growth in the E2-positive mice.
In E2-negative mice, development of tumor resistance/growth was delayed in those mice which received Iressa.
Tamoxifen and Iressa together lead to longer term repression of tumor growth than Tamoxifen alone.
These studies support the idea that EGFR/HER2 receptor cross-talk influences de novo and acquired resistance to various endocrine therapies.
Combinations of ER and HER2 receptor blockade might be the optimal approach in patients with tumors which are ER+ and HER2+.
Human clinical trials will need to be performed to address these issues.
Per discussion at the presentation, such trials are in the planning stages.
Oncolink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.
Sep 29, 2011 - For patients with breast cancer and polysomy 17, the true gene status of human epidermal growth factor receptor 2 (HER2) can be effectively determined by use of additional chromosome 17 fluorescent in situ hybridization studies for Smith-Magenis syndrome, retinoic acid receptor alpha, and tumor protein p53 genes, rather than the HER2-to-centromeric probe ratio, according to a study published online Sept. 26 in the Journal of Clinical Oncology.